TRANSFUSION TRIAL TO PREVENT PLATELET ALLOIMMUNIZATIONS

对血小板抗原的同种免疫是最严重的 血小板输注的限制因素。在本申请中， 作为预防同种异体免疫的合作试验的成员，我们 提出了两种可能限制同种免疫的策略， 来源于急性非淋巴细胞白血病患者的治疗：1. 通过匹配HLA抗原选择血小板供体，特别是 所谓的“公共”抗原; 2.从血小板中除去白细胞 产品过滤在合作研究中，我们可以 如果被选中，则执行其他策略。 我们还提出了跟踪同种免疫发展的方法 针对HLA和血小板特异性抗原，并用于确定 同种免疫的流行病学。

Alloimmunization to antigens on platelets is one of the most severe limiting factors in platelet transfusion. In this application to become a member of a cooperative trial for the prevention of alloimmunization, we propose two strategies which might limit alloimmunization from this source in patients treated for acute non-lymphocytic leukemia: 1. selection of platelet donors by matching HLA antigens, particularly the so-called "public" antigens; 2. removal of leukocytes from platelet products by filtration. In a cooperative study, we would be able to implement other strategies if they were selected. We also propose methods for following the development of alloimmunization to both HLA and platelet-specific antigens and for determining the epidemiology of alloimmunization.